WHO recommends two new drugs against Ebola

The World Health Organization (WHO) has recommended two new prescription drugs - mAb114 (Ansuvimab, Ebanga) and REGN-EB3 (Inmazeb) based on monoclonal antibodies - to treat the diseases caused by the Ebola virus.

Report informs, citing TASS, that based on a systematic review and meta-analysis of randomized clinical drug trials, WHO has issued a strong recommendation for the use of these drugs in Ebola disease. Janet Diaz, Head of WHO Clinical Care, said at a briefing in Geneva on Friday that Ansuvimab and Inmazeb reduce patient mortality by 60%. These drugs have been tested during the Ebola outbreaks in Africa. In particular, the largest study was conducted in the Democratic Republic of the Congo (DRC).

In the Ebola treatment guidelines, the WHO also advised that ZMapp and Remdesivir should not be used as medicines for the disease.